150 related articles for article (PubMed ID: 36394748)
1. First case presentation of refractory pediatric bullous lupus erythematosus (BSLE) treatment with belimumab.
Zeng HQ; Lu XP; Yan ZB; Ye ZZ
Eur Rev Med Pharmacol Sci; 2022 Nov; 26(21):7980-7985. PubMed ID: 36394748
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of bullous lupus with corticosteroids and belimumab: A case report.
Keshavamurthy C; Fibeger E; Virata A; Bansal P
Mod Rheumatol Case Rep; 2023 Jan; 7(1):52-56. PubMed ID: 35538618
[TBL] [Abstract][Full Text] [Related]
3. Bullous systemic lupus erythematosus: An uncommon manifestation in pediatric population.
Hasbún Z MT; Rollan MP; Chaparro R X; Fischer S C; Castrillón V A; González B S; Reculé F
Andes Pediatr; 2021 Jun; 92(3):428-433. PubMed ID: 34479250
[TBL] [Abstract][Full Text] [Related]
4. Clusters of clinical and immunologic features in patients with bullous systemic lupus erythematosus: experience from a single-center cohort study in China.
Qiao L; Zhang B; Zheng W; Li M; Zhao Y; Zeng X; Zhang F; Wang L; Li L
Orphanet J Rare Dis; 2022 Jul; 17(1):290. PubMed ID: 35871005
[TBL] [Abstract][Full Text] [Related]
5. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab.
Guzman M; Hui-Yuen JS
Drug Des Devel Ther; 2020; 14():2503-2513. PubMed ID: 32612353
[TBL] [Abstract][Full Text] [Related]
6. Bullous systemic lupus erythematosus successfully treated with rituximab.
Lowe CD; Brahe CA; Green B; Lam TK; Meyerle JH
Cutis; 2019 Jun; 103(6):E5-E7. PubMed ID: 31348461
[TBL] [Abstract][Full Text] [Related]
7. Bullous Systemic Lupus Erythematosus as an Initial Manifestation of SLE.
Fujimoto W; Hamada T; Yamada J; Matsuura H; Iwatsuki K
J Dermatol; 2005 Dec; 32(12):1021-7. PubMed ID: 16471470
[TBL] [Abstract][Full Text] [Related]
8. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases.
de Risi-Pugliese T; Cohen Aubart F; Haroche J; Moguelet P; Grootenboer-Mignot S; Mathian A; Ingen-Housz-Oro S; Hie M; Wendremaire N; Aucouturier F; Lepelletier F; Miyara M; Bader-Meunier B; Rémy P; Fabien N; Francès C; Barete S; Amoura Z
Semin Arthritis Rheum; 2018 Aug; 48(1):83-89. PubMed ID: 29191376
[TBL] [Abstract][Full Text] [Related]
9. Bullous systemic lupus erythematosus with lupus nephritis: a rare case of a subepidermal bullous disorder in a child.
Poojary S; Rais S
Cutis; 2012 Jan; 89(1):17-21. PubMed ID: 22439305
[TBL] [Abstract][Full Text] [Related]
10. Bullous lupus as the first manifestation of systemic lupus erythematosus in the pediatric population: A diagnostic challenge in daily practice.
Torres Saavedra FA; Campo LR; Mendez MV; Barreneche NM; Suaza GAV; Restrepo JDR; Martinez-Gomez M
Lupus; 2020 Dec; 29(14):1937-1942. PubMed ID: 32842868
[TBL] [Abstract][Full Text] [Related]
11. Successful Treatment with Belimumab in a Patient with Refractory Systemic Lupus Erythematosus after Initiation of Hemodialysis: Considering the Synergistic Effect of Belimumab and Immunological Burn-Out Phenomenon in End-Stage Renal Disease Patients on Hemodialysis.
Karasawa K; Ogura S; Takabe T; Miyabe Y; Iwabuchi Y; Akiyama K; Sato M; Moriyama T; Uchida K; Nitta K
Blood Purif; 2022; 51(2):182-188. PubMed ID: 33895749
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
Hui-Yuen JS; Reddy A; Taylor J; Li X; Eichenfield AH; Bermudez LM; Starr AJ; Imundo LF; Buyon J; Furie RA; Kamen DL; Manzi S; Petri M; Ramsey-Goldman R; van Vollenhoven RF; Wallace DJ; Askanase A
J Rheumatol; 2015 Dec; 42(12):2288-95. PubMed ID: 26523030
[TBL] [Abstract][Full Text] [Related]
13. Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review.
Liang SJ; Zheng QY; Li MS; Lv MY; Chen WT; Yang Y
Clin Rheumatol; 2022 Aug; 41(8):2561-2569. PubMed ID: 35524885
[TBL] [Abstract][Full Text] [Related]
14. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
15. Bullous Systemic Lupus Erythematosus and Lupus Nephritis in a Young Girl.
Momen T; Madihi Y
Oman Med J; 2016 Nov; 31(6):453-455. PubMed ID: 27974963
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
17. Bullous eruption: a manifestation of lupus erythematosus.
Harris-Stith R; Erickson QL; Elston DM; David-Bajar K
Cutis; 2003 Jul; 72(1):31-7. PubMed ID: 12889712
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of refractory cystitis associated with systemic lupus erythematosus with Belimumab.
Xu L; Song X; Dai Q; Guan T; Zhang Y; Lin N; Wang JA
Int Immunopharmacol; 2021 Jul; 96():107574. PubMed ID: 33836367
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 vaccine-triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors-associated bullous pemphigoid.
Nakahara Y; Yamane M; Sunada M; Aoyama Y
J Dermatol; 2023 Feb; 50(2):162-165. PubMed ID: 36578130
[TBL] [Abstract][Full Text] [Related]
20. Juvenile bullous systemic lupus erythematosus - case report.
Sousa S; Santos MJ
Acta Reumatol Port; 2020; 45(1):74-75. PubMed ID: 32608382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
